Other

Dataset Information

0

Screening lncRNAs that binding with catenin.


ABSTRACT: Because of its insensitivity to existing radiotherapy, namely chemotherapy and targeted treatments, triple-negative breast cancer (TNBC) remains a great challenge to overcome. Increasing evidence has indicated abnormal Wnt/β-catenin pathway activation in TNBC but not luminal or HER2+ breast cancer, and lncRNAs play a key role in a variety of cancers. Through lncRNA microarray profiling between activated and inactivated wnt/β-catenin pathway of TNBC tissues, lnc-WAL (wnt/β-catenin associated lncRNA; WAL) was selected as the top upregulated lncRNA in wnt/β-catenin pathway activation compared with the inactivation group. RIP-seq was used to compare the β-catenin and IgG groups, where lnc-WAL could interact with β-catenin. Clinically, increased lnc-WAL in TNBC tumor tissue was associated with shorter survival. lnc-WAL promoted EMT, the proliferation, migration and invasion of breast cancer stem cells (BCSCs), and TNBC cells. Mechanistically, lnc-WAL inhibited β-catenin protein degradation via Axin-mediated phosphorylation at serine 45. Subsequently, β-catenin accumulated in the nucleus and activated the target genes. Importantly, wnt/β-catenin pathway activation stimulated the transcription of lnc-WAL. These results pointed to a master regulatory role of lnc-WAL/Axin/β-catenin in the malignant progression of TNBC. Our findings provide important clinical translational evidence that lnc-WAL may be a potential therapeutic target against TNBC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE268287 | GEO | 2025/05/24

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
GSE268287_RAW.tar Raw
filelist.txt Txt
Items per page:
1 - 3 of 3

Similar Datasets

2024-07-05 | GSE270306 | GEO
2024-09-02 | BIOMD0000000658 | BioModels
2021-03-05 | PXD021181 | Pride
2022-02-27 | GSE197213 | GEO
2022-04-29 | GSE201526 | GEO
2022-02-22 | GSE197000 | GEO
2022-01-26 | GSE169128 | GEO
2022-12-25 | GSE142702 | GEO
2022-12-25 | GSE136406 | GEO
2024-01-06 | MSV000093784 | MassIVE